Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHEP-004
- Development stage
- Unknown
- Lead developer
- Shepherd Therapeutics
01
Overview
SHEP-004 is an investigational oncology drug candidate being developed by Shepherd Therapeutics for the treatment of various rare cancers, including adenoid cystic carcinoma, adrenocortical carcinoma, carcinoid tumors, cholangiocarcinoma, esophageal cancer, and Ewing's sarcoma. The drug was identified and developed using Shepherd's proprietary DELVE platform, which integrates machine learning, bioinformatics, and mathematics to understand the complex biological mechanisms of rare cancers and identify potential therapeutic targets. As of current reports, specific details regarding the drug's molecular target, modality, and chemical structure remain proprietary.
Beyond the preview
Go deeper on SHEP-004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHEP-004.